Eye scan to detect Alzheimer’s related protein deposits in adults with memory issues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study screens adults with memory complaints or mild cognitive impairment to see if retinal imaging, alongside a blood test, can reveal changes linked to Alzheimer’s disease. Participants will undergo a retinal scan and a blood test during a single visit, with the total participation lasting up to one month. The study requires prior APOE genotyping results to be available to investigators and uses MoCA scores to describe cognitive status. The research is conducted at multiple Abu Dhabi sites led by Eli Lilly and Company, with no active intervention beyond diagnostic imaging and blood testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants who are overtly healthy as determined by medical evaluation, including medical history and physical examination.
* Have mild memory complaints or a diagnosis of mild cognitive impairment.
* Have undergone genotyping for apolipoprotein E (APOE) and are willing to make results available to the investigator.
* Montreal Cognitive Assessment (MoCA) score of greater than or equal to 22 and less than or equal to 28.

Exclusion Criteria:

* Have any medical condition that, in the opinion of the investigator, would be a contraindication to participation in the study.
* Have an existing diagnosis of AD or other dementia.
* Have contradictions to or an allergy to the ophthalmic dilating agents.
* Have known diagnosis of severe glaucoma or severe cataracts; have a significant refractive error (more than 12 diopters \[D\] of spherical equivalent refraction); or have any ocular media opacity that prevents imaging of the retina (that is, severe cataract). Note: mild to moderate cataracts or vision correction with glasses or contact lenses are not exclusion criteria.
* Current or previous treatment with anti-amyloid medications.
* Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

Where it's running

• Sheikh Shakhbout Medical City
  Abu Dhabi, United Arab Emirates Recruiting
• Sheikh Tahnoon Bin Mohammed Medical City
  Abu Dhabi, United Arab Emirates Recruiting
• Burjeel Medical City
  Abu Dhabi, United Arab Emirates Not yet recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HOBSCOTCH-MS: Home-based telehealth cognitive coaching for people with multiple sclerosis

  This program will test whether a home-based telehealth cognitive coaching program (HOBSCOTCH-MS) can improve thinking, memory, and quality of life for people with MS and reduce caregiver burden.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT06951919

• Home-based self-management and cognitive training for brain tumor survivors

  This trial will try a home-based cognitive coaching program to see if it improves thinking and quality of life for adults who survived non-glioblastoma brain tumors, with optional caregiver participation.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT06930846

• Nutrition-based interventions to prevent cognitive decline

  This study is testing if a 6-month nutrition program can help adults at higher risk for dementia keep their thinking skills sharp.

  Recruiting at 2 sites Instituto de Saude Publica da Universidade do Porto · Porto, Portugal and 1 other locations · NCT06853405

• New flutemetamol F18 formulation to see if it works as well as current for brain amyloid imaging

  Researchers are testing a new flutemetamol F18 formulation (GE-287) to see if it identifies brain amyloid as accurately as the current formulation in people 50 and older who are undergoing amyloid PET scans for cognitive decline.

  Recruiting at 5 sites Phase 2 GE Healthcare · Aventura, Florida and 5 other locations · NCT07873463

• Longevity Metrics AI/ML Development Study

  Researchers are testing AI models that score health screening tests and predict outcomes like life expectancy for adults, using ongoing follow-up data.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07808619

• Immersive nature-based wellbeing program for older adults with cognitive impairment

  A nature-inspired immersive virtual reality program is being tested to see if it can improve well-being and daily function for older adults with mild to moderate cognitive impairment.

  Recruiting Consorci Sanitari de Terrassa · Terrassa, Barcelona · NCT07802392

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.